Invivyd (IVVD) Set to Announce Earnings on Thursday

Invivyd (NASDAQ:IVVD) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Invivyd to post earnings of ($0.50) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Invivyd (NASDAQ:IVVD) last posted its earnings results on Thursday, March 28th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.26). On average, analysts expect Invivyd to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Invivyd Stock Up 6.4 %

Invivyd stock opened at $2.51 on Wednesday. Invivyd has a 52 week low of $0.98 and a 52 week high of $5.20. The business’s 50-day moving average price is $3.24 and its 200 day moving average price is $3.11. The firm has a market cap of $299.24 million, a price-to-earnings ratio of -1.39 and a beta of 0.89.

Analyst Ratings Changes

Several brokerages have issued reports on IVVD. Guggenheim upgraded Invivyd from a “neutral” rating to a “buy” rating and set a $9.00 target price for the company in a report on Friday, April 5th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Invivyd in a research report on Monday, March 25th. Finally, Morgan Stanley upgraded shares of Invivyd from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $4.00 to $10.00 in a report on Tuesday, March 26th.

About Invivyd

Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2.